Startup Spotlight

Anomer Bio are reprogramming disease with their proprietary computational models targeting a hugely underexplored area of disease - the glycocalyx...

Bill Carton

May 13, 2026

1 in 6 couples face infertility worldwide, and yet it remains a severely underexplored and undertested area of biology. Virilitas Labs are on a mission to challenge the status quo using cutting-edge genomics technologies, giving couples back control over a major aspect of their lives...

Aonghus Topham

April 28, 2026

The tumour microenvironment presents a major barrier to effective delivery of cancer drugs. Neobe Therapeutics are breaking through this barrier through cutting edge genetic engineering techniques putting them at the forefront of immunotherapy delivery.

Bill Carton

April 6, 2026

Hypoxia — a lack of oxygen — is a cornerstone of many tumours which vastly impairs the effectiveness of cancer therapies. StimOxyGen are breathing life back into cancer treatment with their proprietary technology designed to inject oxygen into tumours, massively increasing the effectiveness of various therapies.

Lucy Ahern

November 6, 2025

GitLife Biotech tackles a key challenge in synthetic biology: proving ownership and tracking provenance of engineered biological assets. Their tools replace outdated methods like lab notebooks and unlock commercial potential for labs and start-ups. They envision widespread adoption — with plans to expand from microorganisms into plants, algae, and mammalian cells.

Lucy Ahern

August 7, 2025

Animal studies have been a pre-requisite for drug discovery since the beginning of clinical trials, but with advances in synthetic biology, is animal testing becoming obsolete in today's drug discovery process? PeptiMatrix are at the forefront of this innovation with their advanced, customisable hydrogel technology, they are poised to take advantage of the drug discovery revolution!

Ariyana Rayatt

May 9, 2025